ES2115003T3 - Aminocicloalcanobenzodioxoles como agentes adrenergicos selectivos beta-3. - Google Patents

Aminocicloalcanobenzodioxoles como agentes adrenergicos selectivos beta-3.

Info

Publication number
ES2115003T3
ES2115003T3 ES93121091T ES93121091T ES2115003T3 ES 2115003 T3 ES2115003 T3 ES 2115003T3 ES 93121091 T ES93121091 T ES 93121091T ES 93121091 T ES93121091 T ES 93121091T ES 2115003 T3 ES2115003 T3 ES 2115003T3
Authority
ES
Spain
Prior art keywords
aminocicloalcanobenzodioxoles
adrenergic agents
selective adrenergic
agents beta
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93121091T
Other languages
English (en)
Inventor
Joseph William Epstein
Gary Harold Birnberg
Gary Edward Walker
Minu Dhanjisha Dutia
Jonathan David Bloom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2115003T3 publication Critical patent/ES2115003T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION ES AGONISTA DE ANTIOBESIDAD/ANTIDIABETES/BETA-3 DE FORMULA (FORMULA) EN DONDE LOS SUSTITUYENTES R0, R1, R4, R4'', R5, R6 O N SON COMO SE DEFINEN EN LA ESPECIFICACION.
ES93121091T 1993-01-29 1993-12-30 Aminocicloalcanobenzodioxoles como agentes adrenergicos selectivos beta-3. Expired - Lifetime ES2115003T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1097393A 1993-01-29 1993-01-29

Publications (1)

Publication Number Publication Date
ES2115003T3 true ES2115003T3 (es) 1998-06-16

Family

ID=21748304

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93121091T Expired - Lifetime ES2115003T3 (es) 1993-01-29 1993-12-30 Aminocicloalcanobenzodioxoles como agentes adrenergicos selectivos beta-3.

Country Status (10)

Country Link
US (2) US5510376A (es)
EP (1) EP0608568B1 (es)
JP (1) JPH072831A (es)
KR (1) KR940018376A (es)
AT (1) ATE163930T1 (es)
CA (1) CA2114359A1 (es)
DE (1) DE69317399T2 (es)
DK (1) DK0608568T3 (es)
ES (1) ES2115003T3 (es)
SG (1) SG47557A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578638A (en) * 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
CA2220759C (en) * 1995-05-12 2009-01-20 Nisshin Flour Milling Co. Ltd. 1,4-benzodioxin derivatives
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
DE69940484D1 (de) 1998-04-06 2009-04-09 Astellas Pharma Inc Verwendung von beta-3-adrenergen-Rezeptoren Agonisten in der Behandlung von Dysurie
ES2347027T3 (es) 1998-05-22 2010-10-22 The Board Of Trustees Of The Leland Stanford Junior University Moleculas bifuncionales y terapias basadas en las mismas.
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
DE10142722A1 (de) * 2001-08-31 2003-03-27 Aventis Pharma Deutschland GmbH, 65929 Frankfurt C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2671507A3 (en) 2005-04-28 2014-02-19 Proteus Digital Health, Inc. Pharma-informatics system
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
CA2752373C (en) 2009-02-20 2017-10-10 To-Bbb Holding B.V. Glutathione-based drug delivery system
IL255113B (en) 2009-05-06 2022-09-01 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79323A (en) * 1985-07-10 1990-03-19 Sanofi Sa Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
US5061727A (en) * 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles

Also Published As

Publication number Publication date
EP0608568B1 (en) 1998-03-11
US5594027A (en) 1997-01-14
DK0608568T3 (da) 1998-09-28
ATE163930T1 (de) 1998-03-15
CA2114359A1 (en) 1994-07-30
KR940018376A (ko) 1994-08-16
DE69317399D1 (de) 1998-04-16
EP0608568A1 (en) 1994-08-03
US5510376A (en) 1996-04-23
JPH072831A (ja) 1995-01-06
SG47557A1 (en) 1998-04-17
DE69317399T2 (de) 1998-07-02

Similar Documents

Publication Publication Date Title
ES2115003T3 (es) Aminocicloalcanobenzodioxoles como agentes adrenergicos selectivos beta-3.
DK0486948T3 (da) Forbindelser, der hæmmer retrovirale proteaser
ATE168992T1 (de) 7-substituierte-9-substituierte glycylamido-6- demethyl-6-deoxytetracycline
DK0553307T3 (da) Herbicide substituerede arylhalogenalkylpyrazoler
TR199901473T2 (xx) Ha�ere �ld�r�c� 1-arilpirazoller
DK0707007T3 (da) Amino(thio)etherderivater som CNS-aktive midler
ES2176776T3 (es) Ligandos del neuropeptido-y.
DE69728761D1 (de) Heterocyclisch substituierte benzolderivate und herbizide
DE69932628D1 (de) Herbizide
KR950700277A (ko) 신규 벤조피란 유도체(novel benzopyran derivative)
ES2136887T3 (es) Derivados antifungicos de sordaridina.
NO995963D0 (no) Karboksamider anvendelige som 5-HTIF-agonister
ES2094136T3 (es) Intermediarios quirales de 1,5-diyodo-2-metoxi o benciloxi.
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
DK719388A (da) Propoxybenzenderivater og fremgangsmaade til fremstilling deraf
ATE250021T1 (de) Hydroxycyclopentanone
EP0841327A4 (en) Triazole antifungal agent
DK0566175T3 (da) 3,4-diaryl-(5H)-furan-2-on-baserede forbindelser med fungicid aktivitet
FI901277A0 (fi) 2,5,6,7-tetranor-4,8-inter-m-fenylen pg1z-derivativ.
ATE72445T1 (de) 4'-epi-4'-aminoanthracycline.
ATE63910T1 (de) Diphenyletherderivate.
ES2017493B3 (es) Herbicidas de difenil-eter.
ATE100996T1 (de) Blattglanzmittel.
DK0381114T3 (da) Exo-3,4-O-benzyliden-3"-demethylchartreusin og salte deraf
MA21366A1 (fr) Herbicides a base de diphenylether.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 608568

Country of ref document: ES